CEL-SCI Corporation Receives Final Canadian Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer

CEL-SCI Corporation CVM announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final “no objection” letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine® in Canada. This final approval was given after CEL-SCI was able to provide facility, manufacturing and stability data for the clinical batches of Multikine. Canadian centers are expected to start enrolling patients within the next month.